Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome

[1]  G. Escolar,et al.  Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. , 2010, Transplantation.

[2]  J. Groothoff,et al.  Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  A. Waters,et al.  Severe atypical HUS caused by CFH S1191L—case presentation and review of treatment options , 2010, Pediatric Nephrology.

[4]  A. Kribben,et al.  Eculizumab for atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[5]  B. Hurault de Ligny,et al.  Safety and Long‐Term Efficacy of Eculizumab in a Renal Transplant Patient with Recurrent Atypical Hemolytic–Uremic Syndrome , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  P. Zipfel,et al.  Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[7]  G. Ariceta,et al.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome , 2009, Pediatric nephrology (Berlin, West).

[8]  R. Gruppo,et al.  Eculizumab for congenital atypical hemolytic-uremic syndrome. , 2009, The New England journal of medicine.

[9]  G. Deschênes,et al.  Secondary failure of plasma therapy in factor H deficiency , 2006, Pediatric Nephrology.

[10]  J. Groothoff,et al.  Complement factor H-associated atypical hemolytic uremic syndrome in monozygotic twins: concordant presentation, discordant response to treatment. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  R. Stefanov,et al.  Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[12]  V. Frémeaux-Bacchi,et al.  Atypical haemolytic uraemic syndrome and mutations in complement regulator genes , 2005, Springer Seminars in Immunopathology.

[13]  J. Groothoff,et al.  Atypical relapse of hemolytic uremic syndrome after transplantation , 2004, Pediatric Nephrology.

[14]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[15]  P. Niaudet,et al.  The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children , 2003, Pediatric Nephrology.

[16]  J. le Gall,et al.  High-Dose Plasma Infusion versus Plasma Exchange as Early Treatment of Thrombotic Thrombocytopenic Purpura/Hemolytic-Uremic Syndrome , 2003, Medicine.

[17]  J. Goodship,et al.  Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. , 2001, American journal of human genetics.

[18]  S. Vesely,et al.  Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome , 2000 .

[19]  R. Koene,et al.  Outcome of renal transplantation , 2000, The Lancet.

[20]  J. Goodship,et al.  Genetic studies into inherited and sporadic hemolytic uremic syndrome. , 1998, Kidney international.